{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:35Z","timestamp":1772164775481,"version":"3.50.1"},"reference-count":55,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA077816"],"award-info":[{"award-number":["CA077816"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA121192"],"award-info":[{"award-number":["CA121192"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01-CX000916"],"award-info":[{"award-number":["I01-CX000916"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA009560"],"award-info":[{"award-number":["T32 CA009560"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We examined the role of SLFN12, a member of the Schlafen (SLFN) family of interferon-regulated genes and proteins in leukemogenesis, and its potential as a therapeutic target in acute myeloid leukemia (AML). We explored the effects of velcrins, a class of small molecules able to modulate SLFN12 biological activity, on AML cells. Velcrin treatment of AML cells stabilized SLFN12 and promoted SLFN12 complex formation with phosphodiesterase 3A or phosphodiesterase 3B. Such effects were associated with growth-inhibitory and proapoptotic responses, as well as potent suppressive effects on leukemic cell growth. In addition, velcrin treatment suppressed clonogenic capacity of primitive leukemic progenitors and significantly extended survival in a mouse AML xenograft model. Taken together, these findings establish an important role of SLFN12 in leukemogenesis and raise the potential for the use of velcrins as a therapeutic strategy for AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our studies identify SLFN12 as a potential target in AML with important clinical\u2013translational implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0283","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:49:17Z","timestamp":1761677357000},"page":"2012-2024","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-0871","authenticated-orcid":false,"given":"Jamie N.","family":"Guillen Maga\u00f1a","sequence":"first","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-2056","authenticated-orcid":false,"given":"Markella","family":"Zannikou","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-6894","authenticated-orcid":false,"given":"Aneta","family":"Baran","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"3Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-0250","authenticated-orcid":false,"given":"Sara","family":"Small","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9994-8579","authenticated-orcid":false,"given":"Michael","family":"Schieber","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0865-1057","authenticated-orcid":false,"given":"Matthew J.","family":"Schipma","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"4Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-2582","authenticated-orcid":false,"given":"Elizabeth T.","family":"Bartom","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"4Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"5Division of Biostatistics and Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-9562","authenticated-orcid":false,"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"5Division of Biostatistics and Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-3620","authenticated-orcid":false,"given":"Diana","family":"Saleiro","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3180-2742","authenticated-orcid":false,"given":"Elspeth M.","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"3Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-850X","authenticated-orcid":false,"given":"Frank","family":"Eckerdt","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-7573","authenticated-orcid":false,"given":"Leonidas C.","family":"Platanias","sequence":"additional","affiliation":[{"name":"1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois."},{"name":"2Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois."},{"name":"3Department of Medicine, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2025111703203399300_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"2025111703203399300_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2025111703203399300_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"2025111703203399300_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"2025111703203399300_bib5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/14656566.2022.2111212","article-title":"Advances in the pharmacological management of acute myeloid leukemia in adults","volume":"23","author":"Numan","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2025111703203399300_bib6","doi-asserted-by":"crossref","first-page":"14543","DOI":"10.3390\/ijms232314543","article-title":"Role of biomarkers in the management of acute myeloid leukemia","volume":"23","author":"Small","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025111703203399300_bib7","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3390\/cancers16101805","article-title":"Schlafens: emerging therapeutic targets","volume":"16","author":"Perez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025111703203399300_bib8","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3390\/cells10092238","article-title":"Schlafens: emerging proteins in cancer cell biology","volume":"10","author":"Al-Marsoummi","year":"2021","journal-title":"Cells"},{"key":"2025111703203399300_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/jir.2012.0133","article-title":"The Schlafen family of proteins and their regulation by interferons","volume":"33","author":"Mavrommatis","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"2025111703203399300_bib10","doi-asserted-by":"crossref","first-page":"1468484","DOI":"10.3389\/fonc.2024.1468484","article-title":"Research progress of the SLFN family in malignant tumors","volume":"14","author":"Yu","year":"2024","journal-title":"Front Oncol"},{"key":"2025111703203399300_bib11","doi-asserted-by":"crossref","first-page":"40333","DOI":"10.1074\/jbc.M110.151076","article-title":"Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells","volume":"285","author":"Katsoulidis","year":"2010","journal-title":"J Biol Chem"},{"key":"2025111703203399300_bib12","doi-asserted-by":"crossref","first-page":"25051","DOI":"10.1074\/jbc.M109.030445","article-title":"Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses","volume":"284","author":"Katsoulidis","year":"2009","journal-title":"J Biol Chem"},{"key":"2025111703203399300_bib13","doi-asserted-by":"crossref","first-page":"33006","DOI":"10.1074\/jbc.M113.460741","article-title":"Expression and regulatory effects of murine Schlafen (Slfn) genes in malignant melanoma and renal cell carcinoma","volume":"288","author":"Mavrommatis","year":"2013","journal-title":"J Biol Chem"},{"key":"2025111703203399300_bib14","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/MCB.00019-15","article-title":"Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells","volume":"35","author":"Sassano","year":"2015","journal-title":"Mol Cell Biol"},{"key":"2025111703203399300_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature11433","article-title":"Codon-usage-based inhibition of HIV protein synthesis by human Schlafen 11","volume":"491","author":"Li","year":"2012","journal-title":"Nature"},{"key":"2025111703203399300_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.imbio.2017.07.002","article-title":"Schlafen 14 (SLFN14) is a novel antiviral factor involved in the control of viral replication","volume":"222","author":"Seong","year":"2017","journal-title":"Immunobiology"},{"key":"2025111703203399300_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1074-7613(00)80663-9","article-title":"Schlafen, a new family of growth regulatory genes that affect thymocyte development","volume":"9","author":"Schwarz","year":"1998","journal-title":"Immunity"},{"key":"2025111703203399300_bib18","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1038\/s41388-021-01761-1","article-title":"Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma","volume":"40","author":"Fischietti","year":"2021","journal-title":"Oncogene"},{"key":"2025111703203399300_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1158\/2767-9764.CRC-22-0192","article-title":"SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression","volume":"2","author":"Fischietti","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2025111703203399300_bib20","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1038\/onc.2017.205","article-title":"Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma","volume":"36","author":"Arslan","year":"2017","journal-title":"Oncogene"},{"key":"2025111703203399300_bib21","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025111703203399300_bib22","doi-asserted-by":"crossref","first-page":"100037","DOI":"10.1016\/j.bneo.2024.100037","article-title":"Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML","volume":"1","author":"Small","year":"2024","journal-title":"Blood Neoplasia"},{"key":"2025111703203399300_bib23","doi-asserted-by":"crossref","first-page":"1248825","DOI":"10.3389\/fonc.2023.1248825","article-title":"Progress in investigating the relationship between Schlafen5 genes and malignant tumors","volume":"13","author":"Tu","year":"2023","journal-title":"Front Oncol"},{"key":"2025111703203399300_bib24","doi-asserted-by":"crossref","first-page":"922138","DOI":"10.3389\/fimmu.2022.922138","article-title":"Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025111703203399300_bib25","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-24-0096","article-title":"A PDE3A-SLFN12 molecular glue exhibits significant antitumor activity in TKI-resistant gastrointestinal stromal tumors","volume":"30","author":"Takaki","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025111703203399300_bib26","first-page":"vdae115","article-title":"Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression","volume":"6","author":"Aquilanti","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2025111703203399300_bib27","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1074\/jbc.RA119.011191","article-title":"Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and Schlafen family member 12","volume":"295","author":"Wu","year":"2020","journal-title":"J Biol Chem"},{"key":"2025111703203399300_bib28","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1158\/1078-0432.CCR-24-2713","article-title":"First-in-human dose-escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors coexpressing SLFN12 and PDE3A","volume":"30","author":"Papadopoulos","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025111703203399300_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2025111703203399300_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41375-024-02437-x","article-title":"Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia","volume":"39","author":"Yang","year":"2025","journal-title":"Leukemia"},{"key":"2025111703203399300_bib31","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acsmedchemlett.4c00336","article-title":"Discovery of BAY 2666605, a molecular glue for PDE3A and SLFN12","volume":"15","author":"Lewis","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"2025111703203399300_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"2025111703203399300_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2025111703203399300_bib34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1182\/blood-2018-08-870089","article-title":"Identification and targeting of novel CDK9 complexes in acute myeloid leukemia","volume":"133","author":"Beauchamp","year":"2019","journal-title":"Blood"},{"key":"2025111703203399300_bib35","first-page":"10","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnetjournal"},{"key":"2025111703203399300_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025111703203399300_bib37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2013a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"2025111703203399300_bib38","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2025111703203399300_bib39","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"2025111703203399300_bib40","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1038\/s41467-021-26546-8","article-title":"Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells","volume":"12","author":"Chen","year":"2021","journal-title":"Nat Commun"},{"key":"2025111703203399300_bib41","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1038\/s41467-021-24495-w","article-title":"Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase","volume":"12","author":"Garvie","year":"2021","journal-title":"Nat Commun"},{"key":"2025111703203399300_bib42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025111703203399300_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41589-022-01170-9","article-title":"Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death","volume":"19","author":"Lee","year":"2023","journal-title":"Nat Chem Biol"},{"key":"2025111703203399300_bib44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.molcel.2019.06.040","article-title":"Estrogen-related hormones induce apoptosis by stabilizing Schlafen-12 protein turnover","volume":"75","author":"Li","year":"2019","journal-title":"Mol Cell"},{"key":"2025111703203399300_bib45","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-020-17052-4","article-title":"An alkaloid initiates phosphodiesterase 3A-Schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity","volume":"11","author":"Ai","year":"2020","journal-title":"Nat Commun"},{"key":"2025111703203399300_bib46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/jm50001a001","article-title":"A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity","volume":"28","author":"Weishaar","year":"1985","journal-title":"J Med Chem"},{"key":"2025111703203399300_bib47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/acsmedchemlett.9b00360","article-title":"Optimization of PDE3A modulators for SLFN12-dependent cancer cell killing","volume":"10","author":"Lewis","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"2025111703203399300_bib48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nchembio.1984","article-title":"Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics","volume":"12","author":"de Waal","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2025111703203399300_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1021\/acsmedchemlett.3c00092","article-title":"Anagrelide: a clinically effective cAMP phosphodiesterase 3A inhibitor with molecular glue properties","volume":"14","author":"Meanwell","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"2025111703203399300_bib50","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1074\/jbc.272.11.6823","article-title":"Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)","volume":"272","author":"Degerman","year":"1997","journal-title":"J Biol Chem"},{"key":"2025111703203399300_bib51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00432-024-05676-8","article-title":"Pan-cancer analysis of DDIT4 identifying its prognostic value and function in acute myeloid leukemia","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025111703203399300_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1152\/physrev.00045.2020","article-title":"Rho GTPase signaling in cancer progression and dissemination","volume":"102","author":"Crosas-Molist","year":"2022","journal-title":"Physiol Rev"},{"key":"2025111703203399300_bib53","doi-asserted-by":"crossref","first-page":"1000996","DOI":"10.3389\/fimmu.2022.1000996","article-title":"The cytokine network in acute myeloid leukemia","volume":"13","author":"Luciano","year":"2022","journal-title":"Front Immunol"},{"key":"2025111703203399300_bib54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025111703203399300_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.13024","article-title":"Frequent genomic abnormalities in acute myeloid leukemia\/myelodysplastic syndrome with normal karyotype","volume":"94","author":"Akagi","year":"2009","journal-title":"Haematologica"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0283\/3666059\/crc-25-0283.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2012\/3671273\/crc-25-0283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/2012\/3671273\/crc-25-0283.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:20:46Z","timestamp":1763367646000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/11\/2012\/767295\/Schlafen-12-Modulation-and-Targeting-in-Acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0283","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30635847","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635835","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635838","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635829","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635841","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635832","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30635844","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8151447","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}